‘Alzheimer’s Talks’ teleconference Oct. 13

The Alzheimer's Talks teleconference series welcomes Dr. Michael Harpold to discuss the work of the LuMind Research Down Syndrome Foundation Tuesday, Oct. 13.

Dr. Harpold, chief scientific officer and chair of LuMind's Scientific Advisory Board, will explain why individuals with Down Syndrome experience Alzheimer's disease earlier and at a much higher incidence and rate. Dr. Harpold will also discuss the latest research advances, which will hopefully help find a treatment for both individuals with and without Down Syndrome.

To register for the Oct. 13 call go to Dr. Michael Harpold.

Alzheimer’s Talks is a monthly teleconference series produced by USAgainstAlzheimer's to raise awareness about issues, and unite advocates with researchers or policy leaders. These informational interactive calls run much like a radio talk show, and provide caregivers, researchers, non-profit leaders, government officials, and other advocates direct access to the nation’s leading researchers in Alzheimer’s disease.

Anyone can join the free call via phone or online, or afterwards through the podcast or transcript.

To register for the call, go to Oct. 13 Alzheimer’s Talks.

Editor's note: USAgainstAlzheimer’s (USA2) is committed to ending Alzheimer's by 2020. USAgainstAlzheimer's presses for greater urgency from government, industry and the scientific community in the quest for an Alzheimer's cure. The organization accomplishes this through effective leadership, collaborative advocacy and strategic investments.

 

USAgainstAlzheimer's and the General Board of Church & Society (GBCS) of The United Methodist Church recently announced the launch of the Faith United Against Alzheimer's Coalition (FUAAC), a cooperative effort to mobilize all elements of the faith community in the fight against Alzheimer’s disease and related dementias.

As founders of the coalition, USAgainstAlzheimer’s and GBCS will work with faith-based organizations to promote dignity, compassionate care and quality of life for individuals with Alzheimer’s disease, provide support for families, and call on industry leaders, community stakeholders and policymakers to work urgently to find disease-modifying treatments and a cure.

Letter to the Editor